798 related articles for article (PubMed ID: 30959156)
1. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
[TBL] [Abstract][Full Text] [Related]
3. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
[TBL] [Abstract][Full Text] [Related]
5. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
6. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
7. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Choi H; Seo GH
J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
[TBL] [Abstract][Full Text] [Related]
8. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
9. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
[TBL] [Abstract][Full Text] [Related]
11. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Chon HY; Ahn SH; Kim YJ; Yoon JH; Lee JH; Sinn DH; Kim SU
Hepatol Int; 2021 Dec; 15(6):1328-1336. PubMed ID: 34799838
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
[TBL] [Abstract][Full Text] [Related]
14. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
Lin CL; Lin YL; Liang KH; Chen LW; Chien CH; Hu CC; Huang TS; Shyu YC; Yeh CT; Chien RN
Clin Ther; 2022 Mar; 44(3):403-417.e6. PubMed ID: 35469645
[TBL] [Abstract][Full Text] [Related]
15. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Shin JW; Jeong J; Jung SW; Lee SB; Park BR; Kim MJ; Park EJ; Park NH
Dig Dis Sci; 2021 May; 66(5):1739-1750. PubMed ID: 32524416
[TBL] [Abstract][Full Text] [Related]
16. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
Kim BG; Park NH; Lee SB; Lee H; Lee BU; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
J Viral Hepat; 2018 Dec; 25(12):1565-1575. PubMed ID: 29998592
[TBL] [Abstract][Full Text] [Related]
17. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
Su F; Berry K; Ioannou GN
Gut; 2021 Feb; 70(2):370-378. PubMed ID: 32229544
[TBL] [Abstract][Full Text] [Related]
18. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
[TBL] [Abstract][Full Text] [Related]
19. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
Lee JH; Kim BK; Park SY; Tak WY; Park JY; Kim DY; Ahn SH; Sinn DH; Kim SU
Eur J Intern Med; 2021 Jul; 89():48-55. PubMed ID: 33810942
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
